Savara: Deep Focus on Lungs

Savara inhalation technology aims to solve poor penetration of drugs into lungs

The objective of most inhalation delivery technologies is to deliver therapeutic directly to the target organ while avoiding systemic issues. Savara Inc. believes its nanocluster dry powder inhalation technology will allow the biotech to deliver more active drug to the deep lung, which the company believes will translate into more efficient delivery and new indications for inhaled therapeutics.

According to CEO Robert Neville, current dry powder delivery technologies rely on bulky carrier molecules like lactose,

Read the full 742 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers